Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (<i>PCSK9</i>) Gain-of-Function Mutations-Reference-Cited by-同舟云学术

Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations

Published:2016 Issue:2 Volume:80 Page:512-518
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Tada Hayato¹,Kawashiri Masa-aki¹,Yoshida Taiji¹,Teramoto Ryota¹,Nohara Atsushi¹,Konno Tetsuo¹,Inazu Akihiro²,Mabuchi Hiroshi¹,Yamagishi Masakazu¹,Hayashi Kenshi¹

Affiliation:

1. Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine

2. Department of Laboratory Science, Molecular Biochemistry and Molecular Biology, Graduate School of Medical Science, Kanazawa University

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/80/2/80_CJ-15-0999/_pdf

Reference39 articles.

1. 1. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998; 82: 57U–66U.

2. 2. Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein(a): A unique risk factor for cardiovascular disease. Clin Lab Med 2006; 26: 751–772.

3. 3. Hobbs HH, White AL. Lipoprotein(a): Intrigues and insights. Curr Opin Lipidol 1999; 10: 225–236.

4. 4. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, et al. Lipoprotein(a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59–67.

5. 5. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195–2199.

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Do genetically determined very high and very low LDL levels contribute to Lp(a) plasma concentration?;Nutrition, Metabolism and Cardiovascular Diseases;2024-08

2. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9;European Journal of Clinical Investigation;2024-06-26

3. Lipoprotein (a) as an Important Residual Risk Factor of Atherosclerotic Cardiovascular Disease Under Optimal Medical Therapies;Journal of Coronary Artery Disease;2024-06-25

4. Clinical Impact of Lipoprotein (a) and Cumulative Low-Density Lipoprotein Cholesterol Exposure on Coronary Artery Disease in Patients with Heterozygous Familial Hypercholesterolemia;Journal of Atherosclerosis and Thrombosis;2024

5. Special Patient Populations;Clinical Lipidology;2024